Zevra Therapeutics Inc

ZVRA

8.600USD

+0.240+2.87%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Zevra Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

68 / 159

Overall Ranking

183 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Zevra Therapeutics Inc Highlights

StrengthsRisks

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 132.38% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 23.61M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 23.61M.

Overvalued

The company’s latest PE is 14.25, at a high 3-year percentile range.

Held by PRFDX

Star Investor PRFDX holds 5.30K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

22.857

Target Price

+165.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Zevra Therapeutics Inc is 7.42, ranking 115 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 26.06M, representing a year-over-year increase of 605.36%, while its net profit experienced a year-over-year increase of 98.36%.

Score

Industry at a Glance

Previous score

7.42

Change

0



Financials

6.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.77

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.64

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Zevra Therapeutics Inc is 7.35, ranking 79 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 14.25, which is 12.79% below the recent high of 16.08 and 1071.16% above the recent low of -138.42.

Score

Industry at a Glance

Previous score

7.35

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Zevra Therapeutics Inc is 8.50, ranking 31 out of 159 in the Pharmaceuticals industry. The average price target is 24.00, with a high of 26.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Zevra Therapeutics Inc is 7.01, ranking 86 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 9.45 and the support level at 7.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Zevra Therapeutics Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 68.01%, representing a quarter-over-quarter decrease of 4.46%. The largest institutional shareholder is The Vanguard, holding a total of 3.31M shares, representing 5.87% of shares outstanding, with 13.60% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

3.68M

-1.09%

Woodline Partners LP

3.48M

-24.69%

The Vanguard Group, Inc.

Star Investors

3.08M

+4.43%

Adage Capital Management, L.P.

2.23M

-46.62%

Nantahala Capital Management, LLC

1.97M

+33.97%

Fidelity Management & Research Company LLC

1.54M

-30.03%

State Street Investment Management (US)

1.43M

+14.95%

Geode Capital Management, L.L.C.

1.30M

+4.66%

Susquehanna International Group, LLP

1.21M

+646.48%

Legal & General Investment Management Ltd.

1.05M

+12.58%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zevra Therapeutics Inc is 5.33, ranking 68 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Zevra Therapeutics Inc’s latest ESG disclosure is at an average level in the Pharmaceuticals industry, showing no material impact on overall risk.

Zevra Therapeutics Inc

ZVRA

7.09 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment